Physician profile
Jonathan C Ashton
NPI 1679352629
$2,849.65
in general payments reported to CMS, 2019-2025
22 companies · $2,019 in 2025
The $2,019 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $830 · 2025: $2,019.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,762 · Education: $87.19.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,762.46 |
| Education | $87.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $822.94 | 2024-2025 | Tezspire, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $354.08 | 2024-2025 | Nucala, Trelegy Ellipta |
| United Therapeutics Corporation | $310.93 | 2024-2025 | Tyvaso, Tyvaso |
| Regeneron Healthcare Solutions, INC. | $221.58 | 2024-2025 | Dupixent |
| Amgen INC. | $207.46 | 2024-2025 | Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.21 | 2024-2025 | Ofev, Jascayd |
| Actelion Pharmaceuticals US, INC. | $109.01 | 2025 | Uptravi, Opsumit |
| Verona Pharma, INC. | $107.30 | 2025 | Ohtuvayre |
| Philips North America LLC | $100.50 | 2025 | Vest Therapy Und |
| Baxter Healthcare | $99.11 | 2024-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Volara System |
| Bayer Healthcare Pharmaceuticals INC. | $91.55 | 2024-2025 | |
| Electromed, INC. | $47.68 | 2025 | Smartvest |
| Vifor Pharma, INC. | $45.45 | 2025 | Zemaira |
| Viatris Specialty LLC | $44.97 | 2025 | Yupelri |
| Lilly USA, LLC | $42.98 | 2025 | Zepbound, Mounjaro |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avadel Cns Pharmaceuticals, LLC | $19.73 | 2025 | Lumryz |
| Fisher & Paykel Healthcare INC | $19.52 | 2025 | Fisher & Paykel Healthcare |
| Takeda Pharmaceuticals U.S.A., INC. | $18.34 | 2025 | Glassia |
| Paratek Pharmaceuticals, INC. | $18.12 | 2024 | Nuzyra |
| Insmed, INC. | $17.38 | 2025 | Brinsupri |
| Axsome Therapeutics, INC. | $15.26 | 2025 | Sunosi |
| Pulmonx Corporation | $13.55 | 2024 | Chartis Catheter, Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Ashton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.